http://medicineworld.org/cancer/lung/lung-cancer-blog.html Lung cancer blog from medicineworld.org adds a personal touch to the stories related to lung cancer. This lung cancer blog brings you stories of hope, stories of survivors and latest news and research related to lung cancer. Sun, 03 Apr 2011 15:49:28 GMT en-us http://medicineworld.org/images/blogs/lung-cancer/lung-cancer.jpg http://medicineworld.org/cancer/lung/lung-cancer-blog.html 116 72 http://medicineworld.org/stories/lead/4-2011/target-for-lung-cancer-chemoprevention.html http://medicineworld.org/stories/lead/4-2011/target-for-lung-cancer-chemoprevention.html Sun, 03 Apr 2011 15:49:28 GMT Researchers have identified a biomarker for measuring the success of lung cancer chemoprevention, an emerging frontier in the fight against this disease that has long been stymied by a lack of measureable outcomes. These study results were presented at the AACR 102nd Annual Meeting 2011, held April 2-6........ ]]> http://medicineworld.org/stories/lead/4-2011/new-target-identified-for-squamous.html http://medicineworld.org/stories/lead/4-2011/new-target-identified-for-squamous.html Sun, 03 Apr 2011 15:49:28 GMT Researchers at the Dana Farber Cancer Institute have identified a mutation in the DDR2 gene that may indicate which patients with squamous cell lung cancer will respond to dasatinib. The findings appear in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, from April 2-6........ ]]> http://medicineworld.org/stories/lead/4-2011/soy-increases-radiations-ability.html http://medicineworld.org/stories/lead/4-2011/soy-increases-radiations-ability.html Sun, 03 Apr 2011 15:49:28 GMT A component in soybeans increases radiation's ability to kill lung cancer cells, as per a research studyreported in the recent issue of the Journal of Thoracic Oncology, the official monthly journal of the International Association for the Study of Lung Cancer. "To improve radiotherapy for lung cancer cells, we are studying the potential of natural non-toxic components of soybeans, called soy isoflavones, to augment the effect of radiation against the tumor cells and at the same time protect normal lung against radiation injury," said Dr. Gilda Hillman, an associate professor in the Department of Radiation Oncology at Wayne State University's School of Medicine and the Karmanos Cancer Institute in Detroit........ ]]> http://medicineworld.org/stories/lead/11-2010/helical-ct-scans-reduce-lung-cancer-mortality.html http://medicineworld.org/stories/lead/11-2010/helical-ct-scans-reduce-lung-cancer-mortality.html Sun, 03 Apr 2011 15:49:28 GMT In a major newly released study announced recently by the National Cancer Institute, scientists including Brown University biostatistian Constantine Gatsonis and colleagues observed that screening for lung cancer using helical Computerized axial tomography scanning reduced lung cancer deaths by 20 percent in comparison to using chest X-rays........ ]]> http://medicineworld.org/stories/lead/10-2010/erlotinib-improves-survival-as-first-line-therapy.html http://medicineworld.org/stories/lead/10-2010/erlotinib-improves-survival-as-first-line-therapy.html Sun, 03 Apr 2011 15:49:28 GMT For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line therapy with erlotinib nearly tripled progression-free survival in comparison to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting........ ]]> http://medicineworld.org/stories/lead/10-2010/cheek-swab-may-detect-lung-cancer.html http://medicineworld.org/stories/lead/10-2010/cheek-swab-may-detect-lung-cancer.html Sun, 03 Apr 2011 15:49:28 GMT Early detection is critical for improving cancer survival rates. Yet, one of the deadliest cancers in the United States, lung cancer, is notoriously difficult to detect in its early stages. Now, scientists have developed a method to detect lung cancer by merely shining diffuse light on cells swabbed from patients' cheeks........ ]]> http://medicineworld.org/stories/lead/10-2010/half-of-advanced-lung-cancer-patients.html http://medicineworld.org/stories/lead/10-2010/half-of-advanced-lung-cancer-patients.html Sun, 03 Apr 2011 15:49:28 GMT For the first time to date, research reported in the October edition of the Journal of Thoracic Oncology (JTO) sought to determine the use of chemotherapy in a contemporary, diverse non-small cell lung cancer (NSCLC) population encompassing all patient ages. Previous population-based studies have shown that only 20 to 30 percent of advanced patients with lung cancer receive chemotherapy therapy. These studies have previously relied on the Medicare-linked Surveillance, Epidemiology, and End Results (SEER) database, thus excluding the 30 to 35 percent of patients with lung cancer younger than 65 years of age........ ]]> http://medicineworld.org/stories/lead/9-2010/individualized-chemotherapy-in-lung-cancer.html http://medicineworld.org/stories/lead/9-2010/individualized-chemotherapy-in-lung-cancer.html Sun, 03 Apr 2011 15:49:28 GMT Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients will benefit from which regimen of anticancer drugs, if at all. Building on existing knowledge, a study reported in the September edition of the Journal of Thoracic Oncology (JTO), analyzed the usefulness of adjuvant chemotherapy for non-small cell lung cancer (NSCLC) based on the histoculture drug response assay (HDRA). After seven years of study, scientists concluded that the use of adjuvant (post-operative) chemotherapy based on results of the in vitro HDRA improved the survival and prognosis of patients with NSCLC who had undergone surgery and whose results of the HDRA assay showed chemosensitivity to the specific drugs used for therapy........ ]]> http://medicineworld.org/stories/lead/7-2010/abnormal-cells-in-blood-and-lung-cancer.html http://medicineworld.org/stories/lead/7-2010/abnormal-cells-in-blood-and-lung-cancer.html Sun, 03 Apr 2011 15:49:28 GMT A novel approach detects genetically abnormal cells in the blood of non-small cell patients with lung cancer that match abnormalities found in tumor cells and increase in number with the severity of the disease, a research team led by researchers at The University of Texas MD Anderson Cancer Center report in the journal Clinical Cancer Research....... ]]> http://medicineworld.org/stories/lead/6-2010/predicting-success-with-cancer-drugs.html http://medicineworld.org/stories/lead/6-2010/predicting-success-with-cancer-drugs.html Sun, 03 Apr 2011 15:49:28 GMT Scientists at the Translational Genomics Research Institute (TGen), the Van Andel Research Institute (VARI) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have discovered a biomarker that could help in the therapy of patients with an aggressive type of lung cancer. Using a particular biomarker, scientists might better predict which patients with small cell lung cancer are resistant to existing drug therapies, and which ones could benefit from new therapies tailored to their specific needs, as per a scientific paper published recently in the Journal of Thoracic Oncology........ ]]> http://medicineworld.org/stories/lead/6-2010/vandetanib-shows-clinical-benefit-for-lung-cancer.html http://medicineworld.org/stories/lead/6-2010/vandetanib-shows-clinical-benefit-for-lung-cancer.html Sun, 03 Apr 2011 15:49:28 GMT When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted treatment vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, as per research from The University of Texas MD Anderson Cancer Center. The findings, reported in the Lancet Oncology, mark the first clinical benefit of a small molecule targeted agent and standard chemotherapy in combination for lung cancer. The study was first presented at the 2009 Annual Meeting of the American Society of Clinical Oncology........ ]]> http://medicineworld.org/stories/lead/6-2010/selenium-shows-no-benefit.html http://medicineworld.org/stories/lead/6-2010/selenium-shows-no-benefit.html Sun, 03 Apr 2011 15:49:28 GMT Selenium, a supplement taken daily by millions in hopes of protection against cancer and a host of other diseases, has proven to be of no benefit in reducing a patient's risk of developing lung cancer - either a recurrence or second primary malignancy, as per results of an international Phase III clinical trial........ ]]> http://medicineworld.org/stories/lead/4-2010/oldest-lung-cancer-patients.html http://medicineworld.org/stories/lead/4-2010/oldest-lung-cancer-patients.html Sun, 03 Apr 2011 15:49:28 GMT Eventhough more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective therapys for this age group are scarce. Now Italian oncologists are conducting many trials targeting elderly patients with non-small cell lung cancer (NSCLC), and offer a review of the latest findings - and their recommendations - in the current issue of Therapeutic Advances in Medical Oncology, published by SAGE........ ]]> http://medicineworld.org/stories/lead/3-2010/gene-linked-to-lung-cancer-in-never-smokers.html http://medicineworld.org/stories/lead/3-2010/gene-linked-to-lung-cancer-in-never-smokers.html Sun, 03 Apr 2011 15:49:28 GMT A five-center collaborative study that scanned the genomes of thousands of "never smokers" diagnosed with lung cancer as well as healthy never smokers has found a gene they say could be responsible for a significant number of those cancers. In the March 22 on line issue of Lancet Oncology, the scientists reported that about 30 percent of patients who never smoked and who developed lung cancer had the same uncommon variant, or allele, residing in a gene known as GPC5. The research was co-led by researchers at the Mayo Clinic campus in Minnesota, Harvard University, University of California at Los Angeles (UCLA), and MD Anderson Cancer Center. Scientists found in laboratory studies that this allele leads to greatly reduced GPC5 expression, in comparison to normal lung tissue. The finding suggests that the gene has an important tumor suppressor-like function and that insufficient function can promote lung cancer development........ ]]> http://medicineworld.org/stories/lead/2-2010/erlotinib-marginally-cost-effective.html http://medicineworld.org/stories/lead/2-2010/erlotinib-marginally-cost-effective.html Sun, 03 Apr 2011 15:49:28 GMT Weighing both magnitude of survival benefit and expense, scientists observed that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally cost-effective. The results of their economic analysis using clinical trial data were reported in a newly released study published online February 16 in the Journal of the National Cancer Institute....... ]]> http://medicineworld.org/stories/lead/1-2010/lung-cancer-patients-who-quit-smoking.html http://medicineworld.org/stories/lead/1-2010/lung-cancer-patients-who-quit-smoking.html Sun, 03 Apr 2011 15:49:28 GMT People diagnosed with early stage lung cancer can double their chances of survival over five years if they stop smoking compared with those who continue to smoke, finds a study published on bmj.com today. This is the first review of studies to measure the effects of continued smoking after diagnosis of lung cancer and suggests that it appears to be worthwhile to offer smoking cessation therapy to patients with early stage lung cancer........ ]]>